ERBB2 and neoplasm: In conclusion, our cohorts of colorectal tumors have different rates of MMRd, BRAF and PIK3CA mutations, tumor mutational burden, and TOPO1 and Her2/neu expression, providing vital clinical information that has the potential to guide treatment selection for individual patients and change the design of future clinical trials to stratify patients by site of primary tumor.